Clinical Trials Browser

Carcinoma, Squamous Cell × Erlotinib Hydrochloride × Clear all

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00966472 2020-04-21

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Phase 1 Completed

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

68 enrolled 11 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

NCT00369512 2017-05-30

RAD0503

Phase 2 Completed

15 enrolled 9 charts

Tumor-Agnostic

Carcinoma, Squamous Cell, Neoplasms

NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Phase 2 Terminated

13 enrolled 8 charts

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00476476 2015-05-07

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Phase 2 Completed

41 enrolled 7 charts

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00673049 2013-07-24

NSCLC

Phase 3 Terminated

583 enrolled 11 charts

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT00113347 2012-02-27

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1 Completed

10 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Clinical Trials

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

RAD0503

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

NSCLC

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)